Weekly Roundup: July 22, 2019


Max Rex

Episode Description

This week, the P4A team discuss the coverage of Novartis’ Zolgensma in the US in particular how US health insurers have received the gene therapy. Also on the agenda was the impact of Zolgensma’s launch on rival Biogen’s Spinraza and the potential for dominance of the gene therapy in the spinal muscular atrophy landscape.

Presenter: Aparna Krishnan

Contributor: Max Rex

Producer: Aparna Krishnan

Latest episodes

Share this podcast